Skip to main content

Shigella

1
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

EveliQure Biotechnologies
1 program
1
ShigETEC vaccinePhase 2Vaccine1 trial
Active Trials
NCT07049159Recruiting72Est. May 2027
Inventprise
InventpriseWA - Redmond
1 program
IVT Shigella-04PHASE_11 trial
Active Trials
NCT07205926Recruiting60Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2025
2026
2027
EveliQure BiotechnologiesShigETEC vaccine
InventpriseIVT Shigella-04

Clinical Trials (2)

Total enrollment: 132 patients across 2 trials

NCT07049159EveliQure BiotechnologiesShigETEC vaccine

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Start: Jun 2025Est. completion: May 202772 patients
Phase 2Recruiting
NCT07205926InventpriseIVT Shigella-04

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Start: Oct 2025Est. completion: Aug 202660 patients
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 132 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.